• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Effects of flecainide on ventricular function: clinical and experimental correlations.

作者信息

Josephson M A, Ikeda N, Singh B N

出版信息

Am J Cardiol. 1984 Feb 27;53(5):95B-100B. doi: 10.1016/0002-9149(84)90510-1.

DOI:10.1016/0002-9149(84)90510-1
PMID:6695822
Abstract

Flecainide has unusual electrophysiologic properties and a high potency for the suppression of ventricular tachyarrhythmias. Little is known about its inotropic and hemodynamic actions. In isolated rabbit papillary muscle, it produced a concentration-dependent depression of contractile force, the threshold concentration being 1.0 micrograms/ml. In patients undergoing coronary angiography for ischemic heart disease and given 1 (n = 11) and 2 mg/kg (n = 11) of flecainide acetate i.v., there was no change in heart rate or mean arterial pressure. The vehicle in which i.v. flecainide was suspended had no significant effects in 6 patients in whom it was tested. Both doses produced comparable hemodynamic effects irrespective of the level of the left ventricular ejection fraction. The mean right atrial pressure increased by 12% (p less than 0.05) after 1 mg/kg and by 15% (p less than 0.01) after 2 mg/kg of the drug. The corresponding increases in mean wedge pressure were 44% (p less than 0.05) and 33% (p less than 0.05), in mean pulmonary artery pressure 27% (p less than 0.01) and 28% (p less than 0.05), in systemic vascular resistance 10% (p less than 0.05) and 9% (not significant [NS]) and in pulmonary vascular resistance 6% (NS) and 49% (p less than 0.05). Significant decreases in cardiac index (8 and 12%, p less than 0.05), stroke volume index (11 and 15%, p less than 0.01) and stroke work index (12%, p less than 0.05, and 21%, p less than 0.01) as well as in left ventricular ejection fraction (15 and 16%, p less than 0.01) were also induced by the 2 doses of flecainide.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

相似文献

1
Effects of flecainide on ventricular function: clinical and experimental correlations.
Am J Cardiol. 1984 Feb 27;53(5):95B-100B. doi: 10.1016/0002-9149(84)90510-1.
2
Hemodynamic effects of intravenous flecainide relative to the level of ventricular function in patients with coronary artery disease.冠心病患者静脉注射氟卡尼的血流动力学效应与心室功能水平的关系。
Am Heart J. 1985 Jan;109(1):41-5. doi: 10.1016/0002-8703(85)90413-2.
3
Hemodynamic effects of a new antiarrhythmic agent, flecainide (R-818), in coronary heart disease.
Am J Cardiol. 1983 Feb;51(3):422-6. doi: 10.1016/s0002-9149(83)80073-3.
4
The haemodynamic effect of intravenous flecainide acetate in patients with coronary artery disease.静脉注射醋酸氟卡尼对冠心病患者的血流动力学影响。
Br J Clin Pharmacol. 1983 Jul;16(1):51-9. doi: 10.1111/j.1365-2125.1983.tb02143.x.
5
Evaluation of flecainide acetate in the management of patients at high risk of sudden cardiac death.醋酸氟卡尼在心脏性猝死高危患者管理中的评估。
Am J Cardiol. 1984 Feb 27;53(5):108B-111B. doi: 10.1016/0002-9149(84)90513-7.
6
Hemodynamic dose-response effects of flecainide in acute myocardial infarction with and without left ventricular decompensation.
Clin Pharmacol Ther. 1985 Jun;37(6):619-24. doi: 10.1038/clpt.1985.99.
7
Flecainide in the treatment of nonsustained ventricular tachycardia.氟卡尼治疗非持续性室性心动过速
Ann Intern Med. 1986 Oct;105(4):493-8. doi: 10.7326/0003-4819-105-4-493.
8
Flecainide: electrophysiologic and antiarrhythmic properties in refractory ventricular tachycardia.氟卡尼:难治性室性心动过速的电生理及抗心律失常特性
Am J Cardiol. 1985 Apr 1;55(8):956-62. doi: 10.1016/0002-9149(85)90726-x.
9
Haemodynamic and antiarrhythmic effects of intravenous flecainide acetate in chronic congestive heart failure.静脉注射醋酸氟卡尼对慢性充血性心力衰竭的血流动力学及抗心律失常作用
Drugs. 1985;29 Suppl 4:58-64. doi: 10.2165/00003495-198500294-00012.
10
Flecainide: a new prototype antiarrhythmic agent.
Pharmacotherapy. 1985 Jul-Aug;5(4):209-21. doi: 10.1002/j.1875-9114.1985.tb03419.x.

引用本文的文献

1
Flecainide in Ventricular Arrhythmias: From Old Myths to New Perspectives.氟卡尼用于室性心律失常:从旧有误区到新视角
J Clin Med. 2021 Aug 20;10(16):3696. doi: 10.3390/jcm10163696.
2
Mechanisms of flecainide induced negative inotropy: An in silico study.氟卡尼致负性肌力作用的机制:一项计算机模拟研究。
J Mol Cell Cardiol. 2021 Sep;158:26-37. doi: 10.1016/j.yjmcc.2021.05.007. Epub 2021 May 15.
3
Flecainide How and When: A Practical Guide in Supraventricular Arrhythmias.氟卡尼的使用方法与时机:室上性心律失常实用指南
J Clin Med. 2021 Apr 2;10(7):1456. doi: 10.3390/jcm10071456.
4
The Safety and Effectiveness of Flecainide in Children in the Current Era.当前时代氟卡尼在儿童中的安全性和有效性。
Pediatr Cardiol. 2017 Dec;38(8):1633-1638. doi: 10.1007/s00246-017-1707-5. Epub 2017 Aug 24.
5
Flecainide is effective against premature supraventricular and ventricular contractions during general anesthesia.氟卡尼可有效对抗全身麻醉期间的过早室上性和室性收缩。
J Anesth. 1994 Sep;8(3):284-7. doi: 10.1007/BF02514651.
6
Safety of flecainide.氟卡尼的安全性。
Drug Saf. 2012 Apr 1;35(4):273-89. doi: 10.2165/11599950-000000000-00000.
7
The antiarrhythmic effect of flecainide on halothane-epinephrine induced arrhythmias in dogs.氟卡尼对氟烷 - 肾上腺素诱发犬心律失常的抗心律失常作用。
J Anesth. 1990 Oct;4(4):303-8. doi: 10.1007/s0054000040303.
8
Benefit-risk ratio in the treatment of tachyarrhythmias. A clinical judgement.快速性心律失常治疗中的获益-风险比。一项临床判断。
Drugs. 1985;29 Suppl 4:65-7. doi: 10.2165/00003495-198500294-00013.
9
Flecainide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.氟卡尼。对其药效学特性和治疗效果的初步综述。
Drugs. 1985 Jan;29(1):1-33. doi: 10.2165/00003495-198529010-00001.
10
New antiarrhythmic drugs.新型抗心律失常药物。
Drugs. 1988 Mar;35(3):286-319. doi: 10.2165/00003495-198835030-00005.